Latest Myopia News

HOYA Settles Lawsuit with Shanghai Weixing Optical, Enters Licensing Agreement

January 4, 2024

licensing agreement

Photo Credit: E+, Getty Images

SHANGHAI — HOYA Vision Care has settled its lawsuit with Shanghai Weixing Optical, a manufacturer and distributor of lenses in China, and the two companies have now entered into a licensing agreement.

Under the settlement, Shanghai Weixing Optical issued a significant payment to obtain a license covering sales of Shanghai Weixing Optical products utilizing proprietary D.I.M.S. Technology. The license will end after an agreed phase-out period after which Shanghai Weixing Optical products utilizing proprietary D.I.M.S. Technology will be withdrawn from the market. Sale or export of any Shanghai Weixing Optical products that utilize proprietary D.I.M.S. Technology after the phase-out period (regardless of their name or branding) is prohibited under the agreement.

MiYOSMART spectacle lenses, developed in collaboration with PolyU, are a safe, easy to use, effective and non-invasive method to manage myopia in children. Based on a proprietary approach leveraging D.I.M.S Technology (developed based on peripheral hyperopic defocus theory), MiYOSMART spectacle lenses are based on a well-established and widely recognized theory supported by the leading researchers.1,2

The efficacy of MiYOSMART spectacle lenses, proven by a wide spectrum of evidence, has resulted in over 5 million MiYOSMART spectacle lenses having been purchased by parents across the world between its launch in 2018 and August 2023.3

HOYA Vision Care is committed to developing innovative solutions to address the growing problem of myopia progression in children and remains steadfast in its approach to collaborating with leading scientific institutes around the world to contribute to better treatment options that are proven as effective by robust clinical trials. Hoya Vision Care is dedicated to the protection of both consumers and the integrity of its products.

Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.



  1. Lam CSY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-8.
  2. Lam CSY, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13(1):5475.
  3. Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of August 2023.
To Top